Summary of piRNA review

chatgpt.com/c/691ee4e7-72a0-8325-bc4c-7299401d15c9

Here is a detailed annotated-Vancouver-style summary of the review by Cai Y, Huang S, Dong Y, Li S, Jin X: *“PIWI-Interacting RNAs in brain health and disease: biogenesis, mechanisms, and therapeutic horizons”* (Psychopharmacology (Berl). 2025 Nov 3. doi:10.1007/s00213-025-06958-w. PMID: 41182353) PubMed

Citation

Cai Y, Huang S, Dong Y, Li S, Jin X. PIWI-Interacting RNAs in brain health and disease: biogenesis, mechanisms, and therapeutic horizons. *Psychopharmacology (Berl).* 2025 Nov 3. doi:10.1007/s00213-025-06958-w. PMID: 41182353. PubMed

Summary of Content & Key Findings

Background & scope

- The authors outline that PIWI-interacting RNAs (piRNAs) were originally discovered in germ cells (for example in transposon silencing) but now are increasingly recognised in the central nervous system (CNS). PubMed +2 BioMed Central +2
- The review aims to cover: (1) the biogenesis of piRNAs; (2) their molecular mechanisms and regulatory pathways relevant to neurobiology; (3) evidence implicating piRNA dysregulation in neurological/neuropsychiatric disorders; and (4) therapeutic/biomarker implications. PubMed

Biogenesis and general mechanism of piRNAs

- The review summarises how piRNAs are generated: long single-stranded transcripts (from piRNA clusters, intergenic regions, 3′-UTRs, etc) are processed via primary and secondary (ping-pong) pathways to mature ~24–31 nt piRNAs that associate with PIWI proteins. PubMed +2 MDPI +2
- In their canonical role (especially in germ cells), piRNAs loaded into PIWI proteins repress transposons, protect genome integrity, and can direct epigenetic silencing (DNA methylation, histone modifications) via PIWI/HP1 etc. BioMed Central +1
- In the CNS context, the authors highlight that piRNAs are expressed in neurons and glia, may localise in dendrites/synapses, and have potential to regulate neuronal transcriptomes, synaptic plasticity, axonal regeneration, neuroimmune interactions. PubMed

Mechanistic roles in the brain

- The review emphasises several non-canonical functions of piRNAs/PIWI in neural contexts:
  - Regulation of neuronal development: e.g., neural stem cell differentiation, migration, axon/dendrite growth, spine morphogenesis. PubMed
  - Synaptic plasticity: Modulating dendritic translation, synapse structure/strength (for instance a hippocampal piRNA DQ541777 was previously shown to affect dendritic spine area). MDPI +1
  - Axonal regeneration and repair after injury.
  - Neuroimmune-glial interactions: piRNAs may influence microglia/astrocyte gene expression, inflammatory signalling.
- The authors point out that the mechanistic understanding in brain is still in early stages; many associations exist but causality, specificity, and downstream targets remain to be fully worked out.

Implication in brain health and disease

- The review collects emerging evidence implicating piRNA dysregulation in various CNS disorders:
  - Neurodegenerative disorders: e.g., Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS). PubMed
  - Cerebrovascular disorders: stroke, ischemia-reperfusion injury.
  - Tumour/oncology in CNS: e.g., glioma (including glioblastoma) where particular piRNAs (e.g., piR-9491, piR-12488) were found to reduce tumour cell colony formation in vitro. PubMed +1
  - Neurodevelopmental/psychiatric disorders: autism spectrum disorder (ASD), schizophrenia.
- A key finding is that piRNAs may serve both as biomarkers (due to altered expression profiles in disease) and as therapeutic targets (modulating piRNA/PIWI pathways might influence disease progression). The authors emphasise translational potential. PubMed

Therapeutic horizons & challenges

- The review discusses possible strategies: modulating piRNA expression (antagomirs/inhibitors, mimics), targeting PIWI proteins, leveraging piRNA signatures for diagnosis/prognosis.

- They highlight major challenges: specificity of piRNA-target interactions; delivery into brain (blood–brain barrier, cell types); off-target effects; lack of deep understanding of piRNA biology in CNS; distinguishing cause versus consequence of disease.
- Importantly, the authors call for more mechanistic work in brain contexts, in vivo models, and translational studies linking human patient data, animal models, and therapeutics.

Relevance to neuro-oncology / gliomas

- Although the review covers glioma in the list of disease contexts, the mechanistic depth specific to neuro-oncology is somewhat limited (given the review's broad scope). However the inclusion of glioma points to the relevance of piRNAs in tumour biology in the CNS, which may intersect with the user's interests in adult/pediatric gliomas, BBB/drug-delivery, etc.
- The review thus opens a potential avenue: exploring whether piRNA/PIWI pathways contribute to glioma stem cell maintenance, invasion, therapy resistance, or may be modulated for therapeutic benefit.

Key Findings / Take-Home Points

1. **piRNAs are active in the CNS**: Although originally studied in germline, piRNAs and PIWI proteins are expressed in brain cell types and may regulate key aspects of neuronal/glial biology (development, plasticity, immunity).
2. **Mechanistic diversity**: In the brain, piRNAs may act via post-transcriptional regulation of mRNAs, influence dendritic/spine structure, regulate neural stem/progenitor cell behaviour, and interact with immune/glial signalling.
3. **Disease association**: Altered piRNA signatures are observed across a range of neurological, psychiatric, and neuro-oncological disorders (AD, PD, stroke, ALS, glioma, ASD, schizophrenia).
4. **Therapeutic/biomarker potential**: piRNAs may serve as biomarkers for early diagnosis or disease stratification; modulation of piRNA/PIWI pathways holds promise for therapy (but is still nascent).
5. **Challenges remain**: Key gaps include: detailed mapping of piRNA targets in brain, in vivo functional studies, brain-specific delivery systems, specificity/side-effect concerns, distinguishing whether piRNA changes are causal or reflective of disease.
6. **Implications for neuro-oncology**: For gliomas (and possibly medulloblastomas), piRNAs may represent unexplored regulators of tumour behaviour (stemness, invasion, therapy resistance) and thus potential therapeutic targets or biomarkers—highlighting a promising but under-explored area.

Relevance to Neuro-Oncology, Paediatric BBB/Drug Delivery

Specific implications:

- The review suggests that piRNA/PIWI pathways might influence tumour cell biology in CNS cancers; exploring this in glioma stem cells (adult or pediatric) could yield novel insights.
- From a drug-delivery/BBB perspective: since piRNAs are small non-coding RNAs, the therapeutic modulation (mimics/inhibitors) would require effective delivery across the BBB (especially in paediatric context) and cell-type specific targeting—so combining piRNA targeting with advanced delivery systems (nanoparticles, convection-enhanced delivery, etc) might be relevant.
- Identifying piRNA signatures in CSF or tumour tissue might serve as biomarkers for disease progression, treatment response, or stratification in paediatric neuro-oncology.
- Mechanistic studies (for example, how piRNAs might regulate glioma invasion, angiogenesis, microenvironment, immune interactions) represent an opportunity for translational research bridging basic RNA biology and neuro-oncology.

Limitations / Caveats

- As it is a review, much of the mechanistic evidence is preliminary, associative, or derived from non-CNS or non-tumour models.
- Many piRNA targets/PIWI interactions in the brain remain unknown; the specificity, redundancy, and off-target effects are still poorly characterised.
- Translation into therapeutics is still in early stage; safety, delivery, and brain-specific targeting issues remain major hurdles.
- For gliomas/paediatric CNS tumours the direct evidence is limited—so while the review highlights potential, actual clinical/experimental data in those specific tumour types may be sparse.

Suggestions for Further Research / Questions to Explore

Based on this review and your interest areas, here are some possible research questions or directions:

- What piRNAs and PIWI proteins are differentially expressed in glioma (adult and paediatric) compared to normal brain (and across glioma sub-types)?
- Do any piRNAs regulate glioma stem cell phenotypes (self-renewal, invasion, therapy resistance)?

- Can piRNA expression profiles in CSF or tumour tissue serve as biomarkers for prognosis or treatment response in paediatric neuro-oncology?
- What delivery platforms (lipid nanoparticles, exosomes, viral vectors) have been used or could be used for modulating piRNAs in the brain? How do they perform in paediatric/BBB contexts?
- Could combinations of piRNA modulation with existing therapies (radiation, chemotherapy, immunotherapy) enhance outcomes in glioma?
- Are there piRNA/PIWI pathway alterations that specifically modulate the tumour microenvironment in CNS tumours (e.g., immune cells, glial support, vascular interactions)?
- How do developmental stage and maturity (paediatric vs adult) influence piRNA/PIWI biology in brain tumours and normal brain?